Cellular and Molecular Pathology Laboratory, Experimental Medicine Centre, Venezuelan Institute of Scientific Investigation (IVIC), Caracas, Venezuela.
Blood Transfus. 2018 Feb;16(2):200-208. doi: 10.2450/2017.0176-16. Epub 2017 May 30.
Anti-RhD antibodies (anti-D) are important in the prophylaxis of haemolytic disease of the foetus and newborn (HDFN) due to RhD incompatibility. Current preparations of anti-D are sourced from hyperimmune human plasma, so its production carries a risk of disease and is dependent on donor availability. Despite the efforts to develop a monoclonal preparation with similar prophylactic properties to the plasma-derived anti-D, no such antibody is yet available. Here we studied the agglutinating, opsonic and haemolytic activities of two recombinant polymeric immunoglobulins (Ig) against the G antigen of the Rh complex.
Recombinant polymeric anti-G IgG1 (IgG1μtp) and IgG3 (IgG3μtp) were produced in vitro, purified by protein G-affinity chromatography, and analysed by gel electrophoresis. Their agglutinating, opsonic and haemolytic activities were evaluated using haemagglutination, erythrophagocytosis, and complement activation assays.
The recombinant IgG1μtp and IgG3μtp anti-G antibodies ranged from 150,000 to 1,000,000 Da in molecular weight, indicating the formation of polymeric IgG. No complement activation or haemolytic activity was detected upon incubation of RhD-positive red-blood cells with the polymeric anti-G IgG. Both polymers were better opsonins than a prophylactic preparation of plasma-derived anti-D.
The enhanced opsonic properties of the polymeric anti-G IgG1μtp and IgG3μtp could allow them to mediate the clearance of RhD-positive red blood cells from circulation more efficiently than natural or other synthetic prophylactic anti-D options. Their inability to induce complement-mediated haemolysis would be prophylactically convenient and is comparable in vitro to that of the available plasma-derived polyclonal anti-D preparations. The described properties suggest that polymeric antibodies like these (but with anti-D specificity) may be testable candidates for prophylaxis of HDFN caused by anti-D.
抗 RhD 抗体(抗-D)在预防因 RhD 不相容导致的胎儿和新生儿溶血病(HDFN)方面非常重要。目前的抗-D 制剂来源于高免疫人血浆,因此其生产存在疾病风险,并且依赖于供体的可用性。尽管已经努力开发具有与血浆来源的抗-D 相似预防特性的单克隆制剂,但目前还没有这样的抗体。在这里,我们研究了两种针对 Rh 复合物 G 抗原的重组多聚体免疫球蛋白(Ig)的凝集、调理和溶血活性。
体外生产重组多聚体抗-G IgG1(IgG1μtp)和 IgG3(IgG3μtp),通过蛋白 G 亲和层析进行纯化,并通过凝胶电泳进行分析。使用血凝、红细胞吞噬和补体激活测定评估它们的凝集、调理和溶血活性。
重组 IgG1μtp 和 IgG3μtp 抗-G 抗体的分子量范围为 150,000 至 1,000,000 Da,表明形成了多聚体 IgG。在与 RhD 阳性红细胞孵育时,未检测到多聚体抗-G IgG 补体激活或溶血活性。两种聚合物均比血浆来源的预防用抗-D 制剂更好的调理素。
增强的多聚体抗-G IgG1μtp 和 IgG3μtp 的调理特性可能使它们比天然或其他合成预防用抗-D 选项更有效地介导 RhD 阳性红细胞从循环中清除。它们不能诱导补体介导的溶血在预防上是方便的,并且在体外与可用的血浆来源的多克隆抗-D 制剂相当。所描述的特性表明,像这样的多聚体抗体(但具有抗-D 特异性)可能是预防因抗-D 引起的 HDFN 的可测试候选物。